AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Equities researchers at Jefferies Group lifted their FY2019 earnings per share (EPS) estimates for shares of AcelRx Pharmaceuticals in a research note issued on Tuesday. Jefferies Group analyst M. Andrews now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.79) for the year, up from their previous estimate of ($0.80). Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ FY2020 earnings at ($1.06) EPS and FY2021 earnings at ($0.86) EPS.
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. AcelRx Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.21.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) traded up $0.15 during mid-day trading on Thursday, reaching $1.90. The company’s stock had a trading volume of 153,265 shares, compared to its average volume of 383,895. The stock has a market capitalization of $103.84, a P/E ratio of -1.70 and a beta of 2.64. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a 52 week low of $1.55 and a 52 week high of $5.75.
Several institutional investors have recently made changes to their positions in ACRX. Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $530,000. Geller Family Office Services LLC raised its holdings in shares of AcelRx Pharmaceuticals by 175.0% during the fourth quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock valued at $557,000 after acquiring an additional 175,000 shares during the last quarter. Virtu KCG Holdings LLC raised its holdings in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of AcelRx Pharmaceuticals during the fourth quarter valued at approximately $120,000. Finally, Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals during the third quarter valued at approximately $138,000. 13.61% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals Inc Forecasted to Post FY2019 Earnings of ($0.79) Per Share (ACRX)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/02/17/acelrx-pharmaceuticals-inc-forecasted-to-post-fy2019-earnings-of-0-79-per-share-acrx.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.